Heidelberg Pharma AG (Seite 498)

[versuchsprimat]

Wahrlich ein Juwel (Mogli3)

Neues 52 Wochentief. Pressglas ist sogar noch mehr wert.

[Kampfkuh]

Antwort auf Beitrag Nr.: 58.674.591 von BICYPAPA am 11.09.18 21:14:42

Mal eine Frage am Rande an Dich: was hältst Du von Sernova?

[BICYPAPA]

Antwort auf Beitrag Nr.: 58.657.368 von BICYPAPA am 10.09.18 06:30:51

TLX-250 Redectane- Girentuximab

Hier einen brandneues Abstract zu dem Stellenwert dieses Diagnostikum TLX-250- Redctane, das Heidelberg Pharma an Telix auslizensiert hat.

https://www.ncbi.nlm.nih.gov/pubmed/29730017


Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion.
Hekman MCH1, Rijpkema M2, Aarntzen EH2, Mulder SF3, Langenhuijsen JF4, Oosterwijk E4, Boerman OC2, Oyen WJG5, Mulders PFA4.
Author information


Abstract
Based on the high expression of carbonic anhydrase IX (CAIX) in 95% of clear cell renal cell carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection of ccRCC. This clinical study explores the value of 89Zr-labeled girentuximab positron emission tomography/computed tomography (PET/CT) imaging in diagnostic challenges regarding ccRCC. PET/CT imaging was performed 4 or 5 d after injection of 89Zr-girentuximab in patients with a primary renal mass (n=16) or a history of ccRCC (n=14). Scans were used for decision making (surgery/active surveillance) in case of indistinct renal masses. All resected PET-positive primary lesions proved to be ccRCC, while no lesion progression was seen in PET-negative masses. In patients suspected of recurrent/metastatic ccRCC, PET/CT with 89Zr-girentuximab was useful to confirm or exclude ccRCC, evaluate the extent of the disease, and differentiate from other cancers. In this group, 89Zr-girentuximab PET/CT resulted in a major change in clinical management in five patients (36%), while in three patients (21%) repeat biopsies could be avoided. We conclude that 89Zr-girentuximab PET/CT is a valuable diagnostic tool that can guide clinical decision making in case of diagnostic dilemmas concerning ccRCC suspicion.
PATIENT SUMMARY:
Positron emission tomography/computed tomography imaging with 89Zr-girentuximab can be a valuable diagnostic tool to identify clear cell renal cell carcinoma.

[BICYPAPA]

Antwort auf Beitrag Nr.: 58.648.134 von BICYPAPA am 08.09.18 07:22:49

Advanced Proteome

Quelle: https://www.stockwatch.com/News/Item.aspx?bid=Z-C:APC-265765…

Ausschnitt Heidelberg Pharma:
Collaboration with Heidelberg Pharma


Antibody-drug conjugates (ADCs), targeted for cancer indications, have been actively pursued for two decades, but have suffered from stability problems and product heterogeneity. Nevertheless, even a highly heterogeneous first generation ADC has had clinical and commercial impact with sales near a billion USD per annum, highlighting the great opportunity for improved versions. The combination of Advanced Proteome Therapeutics's proprietary site-selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology, featuring the mushroom toxin amanitin, has yielded novel antibody-amanitin conjugates of high purity and chemical stability. Controlled conjugation methods have led to conjugates that possess high target-specific cytotoxic potency against three cancer cell lines. An antibody-amanitin conjugate has been scaled up for testing in animal tumor models, which has proceeded beyond the 4th quarter (ended July 31st). Initial results from these studies are still being tabulated, but nearing completion, and will be reported on as soon as the analysis of data is completed, within the next few weeks.

[Stoxtrayder]

Dem Kurs scheint es leider (noch) nicht zu interessieren.

Vielleich, wenn von Magenta die ersten (Meilenstein-) Zahlungen fließen...

Dann müßte allerdings eine Neubewertung hier stattfinden. Wenn das dann ähnlich wie bei Affimed zuletzt passiert, hätte ich nichts dagegen. ;-)

[BICYPAPA]

Antwort auf Beitrag Nr.: 58.657.296 von BICYPAPA am 10.09.18 05:44:22

Indikationserweiterung Redectane TLX-250

About TLX250 (89Zr / 177Lu-Girentuximab)
Telix’s TLX250 program is based on the use of an anti-carbonic anhydrase IX (CAIX) antibody (girentuximab), to deliver diagnostic (89Zr for PET imaging) and therapeutic (177Lu) radiation to patients with CAIX-positive tumours. A number of Phase I, II and III trials have successfully explored the utility of girentuximab-targeted radiation delivery for clear cell renal cell carcinoma (ccRCC) and Telix is preparing to commence a multi-centre Phase III imaging trial (89Zr-girentuximab), with a bridging study already in progress.
While CAIX has a long, well-known association with tumour aggressiveness, hypoxia and disease severity in ccRCC patients, it has also been identified as a cancer-specific marker in more than 20 different cancer types. A recent meta-analysis evaluated data from 24,523 patient samples over 147 independent, published studies and revealed statistically significant correlations between CAIX expression and patient endpoints including overall survival and progression-free survival1.

Quelle:https://globenewswire.com/news-release/2018/08/23/1556199/0/…

[BICYPAPA]

Antwort auf Beitrag Nr.: 58.648.506 von BICYPAPA am 08.09.18 09:13:57

Telix on trading halt

Bin mal gespannt, was dahinter steckt.

Hab noch eine Meldung aus Japan zu TLX-250 Redectane zur Partnerschaft von TLX-250 in Japan entdeckt.

MELBOURNE, Australia and KYOTO, Japan and TOKYO, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) ("Telix", the "Company"), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), and Nihon Medi-Physics Co., Ltd. ("NMP"), a leading manufacturer and supplier of radiopharmaceuticals and related products in Japan, have today announced that they have entered into a memorandum of understanding (MOU) for a commercial partnership in renal cancer imaging for the Japanese market.
The agreement between Telix and NMP is focused on Telix's TLX250 imaging program for renal cancer with Positron Emission Tomography (PET). Under the terms of the agreement, Telix and NMP will work together to establish a commercial partnership for TLX250 in Japan, with the objective of appointing NMP as an exclusive partner for the product in Japan. NMP will also support Telix in the near-term goal of including Japanese patients in Telix's global Phase III development program for TLX250.
Telix Pharmaceuticals Japan President, Dr. Shintaro Nishimura, stated, "NMP is a leading company in the Japanese radiopharmaceutical landscape with a strong track record of stable supply of PET imaging agents. As we develop our Japanese regulatory strategy for TLX250, we are pleased to have the experience and guidance of NMP."
NMP President, Mr. Hisashi Shimoda noted, "The technologies in which diagnostics and therapeutics are integrated will become increasingly important to the personalized medicine strategy for cancer treatment. TLX250 has the potential to become one of the best PET products in this field. Our goal is to identify and enrich our portfolio by new products and technologies that meet unmet medical need. It is our pleasure to collaborate with Telix to deliver new renal imaging capabilities to Japanese patients."

[BICYPAPA]

Antwort auf Beitrag Nr.: 58.648.134 von BICYPAPA am 08.09.18 07:22:49

Quelle und Webseite

Hatte die Quellenangabe zu dem Update vergessen.

Quellenangabe: https://www.advancedproteome.com/2018/06/27/advanced-proteom…

Webseite:https://www.advancedproteome.com/

[BICYPAPA]

Antwort auf Beitrag Nr.: 58.606.593 von BICYPAPA am 04.09.18 07:48:49

Advanced Proteome Therapeutics Update

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report continuing progress on its efforts to develop superior antibody drug conjugates (ADCs).
Proceeding from cytotoxicity studies to the next phase of testing in animals necessitates scaling up processes by a significant factor that often requires outsourcing to other companies at considerable cost and down time. APC can now report that it has achieved a breakthrough in processing development candidates for scale up that will allow the Company to independently supply its partners with material.
The new modified protocol has enabled APC to progress collaborative programs as with Heidelberg Pharma (HDP) (Marketwired – January 08, 2018) by producing scaled-up amounts of antibody-drug conjugates with our proprietary, time-dependent, site-selective linking process. The Company can now handle the additional capacity necessary for animal testing, without resort to outsourcing and provide the requisite amounts of material at modest cost.

Allen Krantz, Chief Scientific Officer of APC, stated that “Our progress in reducing the volumes that required specialized equipment for purifying ADCs will facilitate technology transfer to our partners. The promising cytotoxicity studies that we announced in January provided the impetus for successfully scaling up our conjugative processes to accept a far larger scope of material necessary for the testing of potency and toxicity on animal subjects, which we are proud to have achieved in-house. For example, this technological advance has allowed us to efficiently produce samples for the HDP collaboration, which has now entered the animal phase of testing.”

[chicken123]

Antwort auf Beitrag Nr.: 58.606.593 von BICYPAPA am 04.09.18 07:48:49

Vielen Dank für dein Update und deine weiteren Ausführungen. Sowas bringt in ein Forum richtig gute Qualität. Danke auch an mogli3 und behavior. Freue mich über weiter Informationen.